Buserelin Acetate is a GnRH agonist peptide regulating reproductive hormones. Buy Buserelin peptide powder online to explore fertility and hormone-dependent tumor research.
CAT No: 10-101-07
CAS No:57982-77-1 (net), 68630-75-1 (acetate)
Synonyms/Alias:Buserelin acetate;68630-75-1;Suprecur;Suprefact;Buserelin monoacetate;Buserelin (Acetate);Conceptal;Profact;HOE 766MP;HOE 766 MP;UNII-13U86G7YSP;NSC-725176;13U86G7YSP;HOE 766;HOE-766;Receptal;CHEBI:31324;DTXSID30218712;NSC 725176;BUSERELIN ACETATE (MART.);BUSERELIN ACETATE [MART.];Estomal;Acetate, Buserelin;Buserelin acetate [USAN:JAN];NSC725176;Suprefact Depot;Profact Depot;Suprefact Flakon;BSRL Acetate;Suprecur (TN);Hoe-766 MP;5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide monoacetate (salt);SCHEMBL167553;Buserelin acetate (JAN/USAN);BUSERELIN ACETATE [JAN];BUSERELIN ACETATE [USAN];CHEMBL2106198;DTXCID80141203;PYMDEDHDQYLBRT-DRIHCAFSSA-N;BUSERELIN MONOACETATE [MI];BUSERELIN ACETATE [WHO-DD];HY-13581A;MFCD01716229;AKOS032960353;AKOS040763961;AT41853;CS-5962;FP19363;DA-51475;TS-10343;NS00036669;Buserelin Acetate (57982-77-1 free base);D01831;D-Ser (Bu(t))(6) Pro(9) NEt LHRH Acetate;(Des-Gly10,D-Ser(tBu)6,Pro-NHEt9)-LHRH Acetate;Q27888490;(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(TERT-BUTOXY)-2-[(2S)-2-[(2S)-3-HYDROXY-2-[(2S)-2-[(2S)-3-(1H-IMIDAZOL-4-YL)-2-{[(2S)-5-OXOPYRROLIDIN-2-YL]FORMAMIDO}PROPANAMIDO]-3-(1H-INDOL-3-YL)PROPANAMIDO]PROPANAMIDO]-3-(4-HYDROXYPHENYL)PROPANAMIDO]PROPANAMIDO]-4-METHYLPENTANAMIDO]-5-CARBAMIMIDAMIDOPENTANOYL]-N-ETHYLPYRROLIDINE-2-CARBOXAMIDE; ACETIC ACID;pGlu-His-Trp-Ser-Tyr-D-Ser(t-Bu)-Leu-Arg-Pro-NHEt acetate salt;Estomal;pGlu-His-Trp-Ser-Tyr-D-Ser(t-Bu)-Leu-Arg-Pro-NHEt acetate sal t;6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-1-9-luteinizing hormone-releasing factor monoacetate;
Chemical Name:acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Buserelin Acetate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), is widely recognized for its potent agonistic properties and ability to modulate the hypothalamic-pituitary-gonadal axis. By mimicking natural GnRH, Buserelin Acetate exhibits a high affinity for GnRH receptors, enabling it to regulate the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a controlled manner. Its chemical stability, ease of synthesis, and predictable pharmacological profile have made it a valuable tool in a range of experimental and research settings. Researchers value its capacity to induce reversible suppression or stimulation of gonadotropin release, depending on the dosing regimen and duration of exposure. The peptide's versatility and specificity offer significant advantages in studies requiring precise endocrine manipulation.
Endocrine Research: Buserelin Acetate is extensively utilized in endocrine research to investigate the regulation of reproductive hormones and the feedback mechanisms governing the hypothalamic-pituitary-gonadal axis. By administering this GnRH analog, scientists can simulate both the pulsatile and continuous release of GnRH, allowing for detailed exploration of how LH and FSH secretion is modulated under different physiological and experimental conditions. Such studies are crucial for elucidating the roles of gonadotropins in reproductive biology, understanding disorders of sexual development, and identifying potential therapeutic targets for hormone-related dysfunctions.
Reproductive Physiology Studies: In the field of reproductive physiology, Buserelin serves as a reliable agent for inducing ovulation or spermatogenesis in animal models. Its ability to precisely control the timing and magnitude of gonadotropin release makes it indispensable for synchronizing estrous cycles, facilitating superovulation protocols, and enhancing the efficiency of gamete collection. These applications are particularly valuable in both basic research and the development of assisted reproductive technologies, where synchronization and hormonal control are critical for successful outcomes.
Animal Model Development: The use of Buserelin Acetate in the development of animal models has provided researchers with powerful means to mimic or suppress reproductive function as required. By modulating the activity of the hypothalamic-pituitary-gonadal axis, investigators can create models of hormone-dependent conditions such as polycystic ovary syndrome (PCOS), endometriosis, or hypogonadism. These models enable the study of disease mechanisms, evaluation of new therapeutic approaches, and the assessment of long-term effects of hormone manipulation on various physiological systems.
Cancer Research: Buserelin and related GnRH agonists have found significant application in cancer research, particularly in the study of hormone-responsive tumors. By downregulating the production of gonadal steroids through continuous stimulation and subsequent desensitization of GnRH receptors, Buserelin facilitates the investigation of tumor growth dynamics in hormone-dependent cancers. This approach is instrumental in exploring the molecular pathways involved in tumor progression and in testing the efficacy of novel anti-hormonal strategies in preclinical models.
Veterinary and Agricultural Research: In veterinary and agricultural settings, Buserelin Acetate is employed to optimize reproductive efficiency and manage breeding cycles in livestock. Its application in synchronizing ovulation, improving conception rates, and controlling reproductive timing supports advances in animal husbandry and genetic improvement programs. By enabling precise hormonal interventions, Buserelin contributes to increased productivity and the development of reproductive management protocols that benefit both research and industry.
Peptide-based research involving Buserelin Acetate continues to expand as new questions arise in reproductive biology, endocrinology, and disease modeling. Its high specificity for GnRH receptors, coupled with its controllable pharmacodynamic effects, makes it an enduring choice for scientists seeking to manipulate reproductive hormones in a range of experimental contexts. As research methodologies evolve and interdisciplinary studies become more prevalent, the applications of this GnRH analog are expected to diversify further, supporting innovation in both fundamental science and applied research.
Buserelin acetate appears to cause a progressive blockade of gonadotrophin secretion when administered to female rats for four, eight or 12 days, and an important rebound effect, with accentuated estrogen release already apparent in the first estrous cycle following treatment.
Trindade C R, Camargos A F, Pereira F E L. The effect of buserelin acetate on the uterus of adult rats: morphological aspects[J]. Clin Exp Obstet Gynecol, 2008, 3: 198-201.
A comparison has been established retrospectively between clomiphene citrate-human menopausal gonadotropin (CC-hMG) and buserelin acetate-hMG treatments in in vitro fertilization trials performed over a 3-year period. The analysis of 466 CC-hMG and 319 buserelin acetate-hMG trials shows that buserelin acetate-hMG stimulation generates a greater ovarian response resulting in higher numbers of oocytes being retrieved (6.2 + 3.8 versus 9.3 + 5.2) and fertilized (2.8 + 2.7 versus 4.3 + 3.8). More embryos are thus obtained, allowing a wider choice for intrauterine replacement and cryopreservation. Mean embryonic vitality scores do not differ (4.33 + 1.51 versus 4.44 + 1.54), implying that the embryonic quality remains similar in both treatments. A premature demise of the corpus luteum occurs in a large proportion of buserelin acetate-hMG cycles. However, when suppletive progesterone treatment is given, there is a trend toward a better implantation rate per embryo, and a significantly higher ongoing pregnancy rate is observed in relation to buserelin acetate-hMG treatment (20%) as compared with CC-hMG cycles (14%).
Lejeune B, Barlow P, Puissant F, et al. Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment[J]. Fertility and sterility, 1990, 54(3): 475-481.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More